Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Decrease in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 88,900 shares, a drop of 38.5% from the November 30th total of 144,600 shares. Currently, 2.2% of the shares of the stock are sold short. Based on an average daily volume of 1,760,000 shares, the short-interest ratio is currently 0.1 days.

Virax Biolabs Group Price Performance

NASDAQ:VRAX traded up $0.37 on Friday, reaching $2.10. The stock had a trading volume of 943,034 shares, compared to its average volume of 2,013,462. Virax Biolabs Group has a 1-year low of $0.60 and a 1-year high of $9.00. The stock has a fifty day moving average price of $1.95 and a 200-day moving average price of $2.06.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.